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Portugal 
i CEB – Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal 
j Tiradentes Institute, 150 Mt Vernon St, Dorchester, MA 02125, USA   
A R T I C L E  I N F O   
Keywords: 
Double membrane 
Polymyxin B sulphate 
Lidocaine hydrochloride 
Solid lipid nanoparticles 
Burst release 
Controlled release 
A B S T R A C T   
The aim of this study was to develop and characterize a double layer biomembrane for dual drug delivery to be 
used for the treatment of wounds. The membrane was composed of chitosan, hydroxypropyl methylcellulose and 
lidocaine chloride (anesthetic drug) in the first layer, and of sodium alginate-polymyxin B sulphate (antibiotic) 
nanoparticles as the second layer. A product with excellent thickness (0.01–0.02 mm), adequate mechanical 
properties with respect to elasticity, stiffness, tension, and compatible pH for lesion application has been suc-
cessfully obtained. The incorporation of the drugs was confirmed analysing the membrane cross-sections by 
scanning electron microscopy. A strong interaction between the drugs and the functional groups of respective 
polymers was confirmed by Fourier-Transform Infrared Spectroscopy, thermal analysis and X-ray diffraction. 
Microbiological assays showed a high antimicrobial activity when polymyxin B was present to act against the 
Staphylococcus aureus and Pseudomonas aeruginosa strains. Low cytotoxicity observed in a cell viability colori-
metric assay and SEM analysis suggest biocompatibility between the developed biomembrane and the cell cul-
ture. The in vivo assay allowed visualizing the healing potential by calculating the wound retraction index and by 
histological analysis. Our results confirm the effectiveness of the developed innovative biomaterial for tissue 
repair and regeneration in an animal model.   
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Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal (E.B. 
Souto). 
E-mail addresses: ebsouto@ff.uc.pt (E.B. Souto), patricia_severino@itp.org.br (P. Severino).  
Contents lists available at ScienceDirect 
International Journal of Pharmaceutics 
journal homepage: www.elsevier.com/locate/ijpharm 
https://doi.org/10.1016/j.ijpharm.2020.120001 
Received 12 August 2020; Received in revised form 15 October 2020; Accepted 17 October 2020   
International Journal of Pharmaceutics 591 (2020) 120001
2
1. Introduction 
The treatment of skin lesions is a challenging task due to its high cost, 
prolonged hospitalization of the patients, and partial or permanent loss 
of working capacity. The latest Global Burden Disease study estimated 
that skin disorders are the 4th leading cause of non-fatal disease burden 
worldwide (Karimkhani et al., 2017; Seth et al., 2017). Ideal treatment 
approaches should include the stimulation of wound granulation, 
decrease of oedema, fluid and debris, and also the reduction of local 
bacterial contamination and pain (Andersen, 2019). The loss of skin 
integrity results in an imbalance of tissue homeostasis, as the complex, 
multifactorial, and continuous tissue repair process involves specific 
cellular mechanism and extracellular elements, such as cytokines and 
growth factors (Milcheski et al., 2017). 
The use of biomaterials for wound healing has received increasing 
interest over the last years (Barbosa et al., 2016; Diniz et al., 2020; 
Hissae Yassue-Cordeiro et al., 2019). Biomaterials have been widely 
used in the fabrication of several controlled drug delivery systems 
(Gupta et al., 2017; Ramasamy et al., 2020; Ramasamy et al., 2017). For 
skin administration, the drug delivery system should be adhesive to 
maximize the contact with the epidermis and offer a prolonged release 
of the drug over an estimated time-period at the lesion area (Fonseca- 
Santos and Chorilli, 2017; Souto et al., 2017). Natural biopolymers (e.g. 
chitosan, collagen, hyaluronic acid, and gelatine), have been widely 
employed either alone or in combination, with proven advantages in 
optimizing the wound healing process (Chantre et al., 2019; Severino 
et al., 2018). 
The qualitative and quantitative selection of the excipients is 
instrumental in formulation development since these latter influence the 
spatial and temporal release of the drug from the delivery system 
significantly, and thus its therapeutic performance. It should be there-
fore carefully considered the physicochemical characteristics that in-
fluence adherence, mucosal irritation, and uncomfortable feeling 
(Morales et al., 2017; Teo et al., 2017). Membrane devices are a prom-
ising alternative for wound healing; the muco-adhesiveness is a strategy 
to increase the residence time of drugs in the body, improving its 
bioavailability and therapeutic efficacy. Also, membranes can promote 
the gradual release of drugs at specific target sites, thus reducing the 
systemic drug toxicity (Desai, 2018). 
Among natural polymers, alginate is considered a hemocompatible 
biomaterial, easily metabolised and does not undergo accumulation in 
any organ or tissue. Likewise, its solubility in aqueous medium makes 
this polymer an interesting alternative for biomedical applications. 
Alginate is obtained from the extraction of algae and it is characterized 
as being an anionic polymer derived from the sodium salt of alginic acid. 
Due to its inert, biocompatible, biodegradable character, alginate is 
being widely used in healing processes, being able to form membranes 
with excellent mucoadhesive properties. In the literature, several uses of 
alginate for skin healing have been described (Diniz et al., 2020; 
Shtenberg et al., 2018). The mechanically resistance promoted by the 
combination of two oppositely charged polyelectrolytes is commonly 
used in the fabrication of particles, sponges, and membranes. 
Polymyxins are polypeptide antibiotics with intense action on gram- 
negative bacteria, which is desired in wound infections (Harm et al., 
2016). Also, the presence of an anesthetic drug in the developed mem-
brane for burst release promotes pain relief. Lidocaine is an amide-type 
local anesthetic and antiarrhythmic class Ib; due to its biopharmaceu-
tical properties, this drug has been successfully used in a variety of 
formulations for topical anesthesia. Lidocaine shows limited systemic 
absorption and the induced analgesic effect results from the blocking 
sodium channels in afferent nerves (Smith et al., 2018). 
Production of nanoparticles by the formation of a polyelectrolyte 
complex in which electrostatic interaction occurs between the amino 
groups of polymyxins and the carboxyl groups of the alginate, offers the 
possibility to achieve a controlled release of loaded drugs (Severino 
et al., 2015; Severino et al., 2017). We have previously seen that this 
binding keeps the antimicrobial action of polymyxins and controlled 
release. 
Chitosan is also widely employment as biomaterial for skin healing 
(Debone et al., 2019). Chitosan is derived from exoskeleton of crusta-
ceans, it shows hemostatic, fungicidal, antibacterial properties, and the 
ability to stimulate cell migration and proliferation by reorganizing the 
cell histoarchitecture. One of its most common uses is in the formation of 
biomembranes (Barbosa et al., 2016; Behera et al., 2017). Some of the 
drugs already loaded into alginate and/or chitosan membranes reported 
in the literature are ibuprofen (Morgado et al., 2017), norfloxacin 
(Mahmoud and Salama, 2016), prazosin (Kulkarni et al., 2010), nifedi-
pine (Thacharodi and Rao, 1996), among others. 
The aim of this work has been the development and characterisation 
of a double-layer membrane for the dual delivery of the antibiotic 
polymyxin and the local anesthetic lidocaine. A blend of chitosan and 
hydroxypropyl methyl cellulose polymers containing lidocaine has been 
used as the first layer. This layer was then coated with a second layer 
composed of alginate-polymyxin nanoparticles, aiming to achieve a 
burst release of the anesthetic followed by a sustained release of the 
antibiotic drug. 
2. Materials and methods 
2.1. Materials 
Polymyxin B sulphate (PLX) and lidocaine hydrochloride (LCH) were 
kindly provided by Cristalia (Itapira, São Paulo, Brazil). Sodium alginate 
(ALG, 150–170 Da/Protanal® 6650) was received from FMC 
Biopolymer (Philadelphia, PA, USA). Chitosan (CS), with a degree of 
acetylation (DA) of 82.83 ± 3.63 and a molar mass of 296.6 kDa was 
obtained from Polymer (São Paulo, SP, Brazil). Hydroxypropyl methyl 
cellulose (HPMC, Methocel™ K100CR, 80,000–120,000 cP apparent 
viscosity 2% in water at 20 ◦C) and sorbitol were bought from Henri-
farma (São Paulo, SP, Brazil). Double distilled water was used after 
filtration in a Millipore® system (home supplied). All other reagents 
were purchased by Sigma-Aldrich (Sintra, Portugal). 
2.2. Preparation of the dual membranes 
The membranes were produced by the casting method. The first layer 
was composed of CS, HPMC, sorbitol, LCH, and PLX, which were solu-
bilized in an aqueous acetic acid solution (5% w/v). Then, the obtained 
product was poured into Petri dishes and kept in an oven (TECNAL TE- 
393/2, Piracicaba, SP, Brazil) at 40 ◦C for 30 min. The production of the 
PLX-loaded solid lipid nanoparticles (PLX-SLN) (to form the second 
layer) has been previously described by us (Severino et al., 2015). 
Briefly, the aqueous surfactant solution, composed of polysorbate 20 
(0.45 w/v), trioleate sorbitan (0.045 w/v) and heated at 80 ◦C, was 
slowly added to the melted lipid phase (cetyl alcohol 1% w/v) con-
taining PLX. A hot emulsion was obtained by higher shear homogeni-
zation using the Ultra-Turrax® (IKA, model T25, impeller 10 G, 
Königswinter, Germany) for 3 min and applying 10,000 rpm. The hot o/ 
w emulsion was then passed in a high-pressure homogenizer (GEA Niro 
Soavi, model NS1001L2K, Panda 2 K, Parma, Italy) at 80 ◦C applying 
500 bar pressure and 5 homogenization cycles. Freshly prepared PLX- 
SLN were poured onto the previous layer, maintaining them in an 
oven at 40 ◦C for 24 h. Table 1 shows the selected concentrations of each 
component used in the formulation. 
2.3. Scanning electron microscopy 
The morphology of the membranes was analysed by scanning elec-
tron microscopy (SEM). The membranes were cut in 2 × 1 cm2 sections 
and maintained in an environment with silica gel activated for 24 h. 
These were then cryofuffed with liquid nitrogen, fixed in suitable 
metallic support (mini Sputter coater, SC 7620) by depositing a thin 
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layer of gold (thickness of 92 Å) on their surfaces and images were taken 
with a Hitachi TM 3000 micoscope (Tokyo, Japan) (Debone et al., 
2019). 
2.4. Fourier-Transform Infrared Spectroscopy 
The analyses were performed on an average of 32 scans, in the range 
of 4000–500 cm− 1. The equipment used was a Fourier Transform 
Infrared Spectrometer (FTIR – Nicolet IS10 – Thermo Scientific, Wal-
tham, MA, USA) (Yassue-Cordeiro et al., 2018). 
2.5. Thermal analysis 
Thermograms curves were determined using a thermoanalytical 
balance (DTG-60H, Shimadzu, Tokyo, Japan). Membranes were care-
fully weighed (~1.50 mg) in a platinum pan and heated to temperatures 
ranging from 25 to 500 ◦C (10 ◦C/min) under a dynamic nitrogen at-
mosphere (100 mL/min). Differential Scanning Calorimetry (DSC) an-
alyses were performed using a DSC-60 thermal analysis system 
(Shimadzu, Tokyo, Japan). Approximately 10 mg of samples were 
weighed into an aluminum pan, sealed, and heated ranging from 25 to 
320 ◦C under a heating rate of 5 ◦C min− 1 in a nitrogen inert atmosphere 
(45 mL/min) (Debone et al., 2019). 
2.6. Mucoadhesion 
Mucoadhesion properties were evaluated using a texture analyzer 
(TA.XT plus, Stable Micro Systems, Godalming, UK) with 50 N load cell, 
according to the procedure described by (Fransén et al., 2008). The 
cylindrical ended probe (10 mm diameter) was moved downward with a 
speed of 2.0 mm/s until contact with the sample; contact was main-
tained for 30, 60, and 180 s. Afterward, the probe was raised at 2.0 mm/ 
s. The maximum force required to detach the probe from the sample 
could be detected directly using Texture Exponent Lite software. The 
total amount of force involved in probe withdrawal (Wad – µJ) was 
determined by calculating the area under the force versus distance 
curve. The tests were repeated six times in a compression test mode with 
2 mN of triggered force (Severino et al., 2018). 
2.7. Mechanical properties of membranes 
The elongation at break, tensile strength, and Young’s modulus was 
measured using a texture analyzer (TA.XT2, Godalming, UK) equipped 
with a 5 kg load cell. Membranes were cut into 8 cm2 (2 × 4 cm) sec-
tions. Specimens were tested for breaking at a crosshead speed of 2 
mm⋅s− 1 and a displacement of 10 mm. Analyses were performed in 
triplicate. 
2.8. Degree of swelling 
The membranes were swelled in phosphate-buffered saline (PBS). 
Membranes of 2 cm diameter were weighed and immersed in 30 mL PBS 
(pH 6.8) at 37 ◦C, removed at time intervals of 2 h (0, 2, 4 and 6 h) and 




× 100 (1)  
where DS stands for the degree of swelling (%), mi for the initial sample 
mass (g), and mf for the wet mass at different sample times (g). Results 
were expressed as the average of three measurements. 
2.9. Cell viability – MTT assay 
The cell viability assay was performed using L929 mouse fibroblasts 
cell line. The methodology was based on the ISO 10993-5 (2009) (ISO, 
2009). L929 cells were seeded into 96-well plates (0.1 × 106 cells/well) 
and cultured in Dulbecco’s Modified Eagle Medium (DMEM). Cell 
viability was assessed via the colorimetric method using Methyl Thia-
zolyl Tetrazolium (MTT). Absorbance was measured at a wavelength of 
570 nm using an automated plate reader (DTX880 Multimode Detector, 
Beckan Coulter Inc., Packard, ON, Canada). Tests were performed in 
quadruplicate and then normalized according to Eq. (2). 
%Cell viability =
Abs (treated cells) − Abs (blank)
Abs (positive control) − Abs (blank)
× 100 (2)  
where Abs (treated cells) is the absorbance in the presence of the tested 
membrane, Abs (positive control) is the absorbance of the cells without 
treatment, and Abs (negative control) is the absorbance with the 
membrane drug. 
2.10. Cell adhesion and proliferation by SEM 
L929 fibroblasts were inoculated at a density of 1 × 105 cells/sample 
and incubated in DMEM culture medium supplemented with 10% fetal 
bovine serum, 1% L-glutamine and 1% penicillin–streptomycin and 
incubated at 37 ◦C in an atmosphere containing 5% CO2 for 24 h. The 
membranes were sterilized by UV light for 30 min each face, as it was a 
membrane. Samples were rinsed with PBS and fixed in Karnovsky so-
lution (4% formaldehyde, 2.5% glutaraldehyde in PBS) for 24 h. The 
cells were rinsed in PBS and dehydrated with successive and growing 
baths of alcoholic solutions. Then, it was immersed in a 50:50 (v: v) 
ethanol/hexamethyldisilane (HMDS) solution for 30 min follow up a 
100% HMDS immersion during 30 min, and finally removed and dried 
under exhaustion for 24 h. The samples were metalized with gold and 
examined by SEM (SEM, Jeol carry scope JCM-5700, Tokyo, Japan). 
2.11. Minimum inhibitory concentration and inhibition halo 
The minimum inhibitory concentration (MIC) determined the anti-
microbial activity of the membrane to get therapeutic levels with lethal 
or inhibitory capacity for the growth of strains of Staphylococcus aureus 
(ATCC 25923) and Pseudomonas aeruginosa (ATCC 27853). Colonies 
were harvested and resuspended to 1.5 × 108 UFC⋅mL− 1 (turbidity 
equivalent to 0.5 McFarland standard scale). The bacterial solution was 
diluted to 1 × 105 UFC⋅mL− 1 in Mueller Hinton Broth. Samples were 
diluted in DMSO at concentrations of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8% 
in a volume of 50 µL medium, were diluted at concentrations since 1.0 
until 0.0019531 mg⋅mL− 1. The negative control was 0.1 mL of Mueller 
Table 1 
The composition of membranes formulations.  
Membranes Layer 1 Layer 2 
Chitosan HPMC Sorbitol Lidocaine Hydrochloride Polymyxin sulfate Sodium alginate Polymyxin sulfate 
F1      2  
F2 1       
F3 1 1    2  
F4 1 1 1 0.05 0.185 2 0.240 
*Percentage values. 
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Hinton Broth, and the positive control was 0.05 mL Mueller Hinton 
Broth and 0.05 mL bacterial solution at 1 × 105 UFC⋅mL− 1 dilution. 
Plates were incubated at 37 ◦C for 20 h. The bacterial suspension 
(Staphylococcus aureus ATCC 25923 and Pseudomonas aeruginosa ATCC 
27853) was prepared for inoculum. The cell culture was performed in 
phosphate buffer pH 6.0. The concentration and turbidity of the inoc-
ulum were standardized, comparing this with the 0.5 standards of the 
McFarland scale. 15 mL of the Muller-Hinton agar was poured into 100 
mm plates and homogenized. After solidification was introduced a swab 
with a bacterial suspension. The seeded plates were allowed to dry for 5 
min at room temperature until agar absorbed and applying to the disc- 
cut membranes 
2.12. Healing activity in vivo 
This study was approved by the Ethics Committee on Animal 
Research of the Tiradentes University (CEUA/UNIT) through Opinion 
No. 011216, the study was conducted within the ethical and legal 
standards, in support of Law No. 11794 of 08.10.2008, which establishes 
procedures for their scientific use, Environmental Crimes Law No. 9.605 
of February 12, 1998 and the Ethical Principles for the Use of Laboratory 
Animals of the Brazilian Society of Laboratory Animal Science (SBCAL/ 
COBEA). The experiments were performed with ≈60 days old male 
Wistar rats (Rattus norvegicus) (200 ± 50 g). The animals were kept in 
plastic cages, lined with shavings under controlled conditions (12 h 
light–dark cycle at 25 ± 2 ◦C and 60% air humidity), receiving com-
mercial feed and water ad libitum. The wounds were performed under 
general anesthesia with an intraperitoneal injection of 0.1 mL/100 g 
weight of a solution consisting of 1 mL of ketamine (50 mg) and 1 mL of 
xylazine (20 mg). The procedure was done with a punch, stainless steel, 
measuring 8.0 mm in diameter, maintained without suture (open) and 
hemostasis. The dorsal region of the animal was standardized for the 
incision taking as reference the spine along the axis of the animal’s body, 
which was trichotomized and performed antisepsis with 1% topical 
povidone-iodine. This incision involves the entire thickness of the 
integument until visualization of the musculature, to keep the fascia 
intact. In the immediate postoperative period, the animals received 10 
mg/kg ketoprofen intramuscularly for three days as a prophylactic dose 
of postoperative symptomatology. 
All animals were identified by groups and each group according to 
the number of days to analyze the healing process (3rd, 7th, 14th, and 
21st day) until euthanasia. Each experimental group and its subgroups 
were named according to the type of coverage used in the surgical 
incision as for the control group (GC) wrinkle without treatment, 
membrane without drug (GF3) and group of membrane-covered wounds 
with drugs (GF4). In the postoperative period, the lesions were controlled 
with photographic images (Sony-branded camera, 10.1 megapixels) and 
measured with a digital caliper at the inner edges of the diameter at 0, 
3rd, 7th, 14th, and 21st days. Each animal was euthanized in a carbon 
dioxide chamber (model CGSCO2G – Beiramar), where they received 
airflow containing 100% CO2 for 5 min. After the death of the animals, 
the similar specimens were removed from the healing area with 3.0 mm 
margins and the biological residues were left in the vivarium for the final 
external destination (Corrêa et al., 2017). 
Removal of the specimens was equivalent to a healing area with a 
0.5 cm margin of intact skin around the lesion, deep to the first muscle 
layer. The removed specimens were fixed in EVA and placed in a plastic 
container with 10% buffered formalin solution and pH 7.4 for fixation. 
They were later hemisected, dehydrated in increasing ethanol solutions 
at 70, 95 and 100%, diaphanized in xylol and embedded in paraffin 
(conventional histological technique). Histological sections were ob-
tained from paraffin-embedded samples and subsequently subjected to 
Haematoxylin/Eosin (HE) and Picrosirius staining (Barreto et al., 2016). 
2.13. Capture and assessment of wound area 
The images were obtained by a camera (Sony 10.1), suspended by a 
tripod with a distance of 30 cm from the evaluated area, designed to 
standardize the capture of the images of the lesions. Wounds were 
measured on days 0 (immediately after surgery), 3, 7, 14 and 21 days 
postoperatively (after euthanasia) with the aid of a digital caliper. From 
the measurements of the wound edges, standardized on the right lateral 
face and lower side, obtaining the value of their area, the wound 
contraction was evaluated by the following Eq. (3): 
Wound contraction = [initial area − day area of measurement] × 100 (3)  
2.14. Statistical analysis 
Two-way analysis of variance (ANOVA) followed by Tukey post hoc 
test and T-test were employed for statistical analysis. P ≤ 0.05 was 
considered indicative of a statistically significant difference. The study 
was conducted using the software Microcal Origin v. 7.0 (Origin Lab 
Corp, Northampton, MA, USA). 
3. Results and discussion 
Images of the surface and the cross-section of the obtained mem-
branes are shown in Fig. 1. Fig. 1(a) and (b) refers to the double layer 
membrane without drug (F3). The thickness of the layers is directly 
related to the high viscosity of the chitosan (CS) solution (Wang and 
Chen, 2014). Fig. 1(c) and (d) refers to the double layer membrane with 
the drug (F4). The uniformly distribution of nanoparticles on the surface 
of the membrane is clearly visible, suggesting that the interconnection 
between ALG and PLX has occurred by ionotropic gelation between the 
amino (NH3) of PLX and the carboxylic group (COO− ) of the alginate 
(Severino et al., 2017). 
FTIR spectrum has been used to identify functional groups through 
the specific binding vibration energy detection signal in each type of 
chemical group. It is widely used to identify unknown substances and 
interactions between substances to form new composite materials. The 
FTIR spectra of the polymers (ALG and CS) and drugs (PLX and LCH) 
were compared with a double layer membrane (F4) and results are 
shown in Fig. 2. 
The main peaks of ALG were 3418 cm− 1, attributed to the stretching 
O–H and 1613 cm− 1, a corresponding carboxylate group (Wu et al., 
2018). The main band of PLX was between 1500 and 1550 cm− 1 cor-
responding to the amine group. The cross-linking of PLX with ALG oc-
curs by the reduction of its hydrophilicity through the interaction of 
opposite charges of the polymer in question (anion) with the drug 
(cation). The bonding between ALG and PLX occurred between the 
carboxyl group (COO–) of the polymer with the amino (NH3+) of PLX 
(between 1500 and 1550 cm− 1). PLX and polymer interaction suggests a 
positive outcome, since free PLX shows high toxicity attributed to its 
amphiphilic and cationic nature (Severino et al., 2015). Therefore, the 
current strategy to minimize the PLX toxicity is to reduce the number of 
cationic residues and its amphiphilic character (Insua et al., 2017). 
The main peak of CS was at 3417 cm− 1, attributed to O–H axial and 
the characteristic band at 1650 cm− 1 was assigned to the –C–O group 
of the CS (Wu et al., 2018). Double membrane with drugs (F4) shows 
spectra of each polysaccharide alone and, as previously noted, they are 
superimposed on the membrane F4, which also presented the charac-
teristic peaks of the drugs, especially that of lidocaine (3300 cm− 1 and 
1550 cm− 1 for amine groups, both of medium intensity), considering 
that this drug does not cross-link because it is only incorporated in the 
membranes. The bands observed were: (i) the axial stretch band of OH, 
attributed to the hydroxyl group present in CS between 3440 and 3480 
cm− 1; and (ii) the 1583 to 1594 cm− 1, related to the amides observed in 
the region of 1500 cm− 1 shown in the spectra of the membrane (F4), CS 
and PLX, which is a cationic drug. The main bands observed in the 
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sample spectra of the samples were similar as those reported in the 
literature (Wu et al., 2018). 
The thermal analyses of the membranes were used to observe the 
interaction between the polymers, and to select the materials with the 
best thermal properties for specific uses. Fig. 3(a) shows the results 
obtained for the monolayer membranes composed by ALG (F1) and CS 
(F2). Fig. 3(b) shows a double layer membrane without drug (F3) and a 
double layer membrane with the drug (F4). Thermograms provide in-
formation about three thermal events, the first one related to dehydra-
tion, and the third associated to the carbonization of the analyzed 
samples (Gallardo-Rivera et al., 2018; Lino et al., 2017). The membranes 
exhibited a loss of mass in different stages depending on their 
Fig. 1. SEM of membrane surfaces/section of membrane fracture (a) and (b) ALG + CS + HPMC + Sorbitol (F3); (c) and (d) Double layer membrane with the 
drug (F4). 
Fig. 2. FTIR spectra of lidocaine chloride (LC), polymyxin sulfate (PLX), so-
dium alginate (ALG), chitosan (CS), and double-layer membrane (F4). Fig. 3. Thermogram F1 (ALG), F2 (CS), F3 (ALG + CS + HPMC + sorbitol) and 
F4 (double layer). 
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composition. The analysis was restricted to the probable interference of 
the presence of the drugs in the membranes. 
In the double-layer membrane (F4) the mass loss started at 26.43 ◦C, 
with a mass loss percentage of 100% for at 382.42 ◦C. It can be observed 
that the decomposition of the double layer membrane with drug pre-
sents only two thermal events, being more accelerated compared to the 
membrane without the drug (F3) that showed three events of mass loss. 
These evidence a change in the thermal stability of the set (membrane) 
with the addition of the proposed drugs, thus showing a probable 
interaction between the polymers, LCH and PLX. 
The decay of LCH was in accordance to those reported by Pathak and 
Nagarsenker (2009). It occurred between 197 ◦C and 263 ◦C with 
endothermic peaks between 212 ◦C and 251 ◦C, similarly to PLX, with a 
thermal degradation with temperatures lower than those of the poly-
mers involved in the sample. Thermal degradation at a lower tempera-
ture in these membranes suggests the complexation between CS and 
drug ions through the formation of ionic bonds between the polymers 
and is possibly associated with the loss of chain organization (Bigucci 
et al., 2008). 
The increase in temperature favors the volatilization of the water and 
consequently an approximation of the polymer chains, and after evap-
oration of the water, a repulsion occurs between the positive charges of 
the chitosan and the positive charges of the drugs promoting the 
expulsion of these from the chain. An observation also happened in the 
study of (Lino et al., 2017) with CS hydrogels for nicotine release. 
Fig. 4 shows the DSC profiles of F1 (ALG), F2 (CS), F3 (double layer 
without drug) and F4 (double layer with the drug). A change between F3 
and F4 was observed confirming the presence of the anesthetic by the 
reduction of the intensity of the melting peak. The addition of PLX 
promoted an increased membrane crystallization as evidenced by the 
exothermic peaks of F4 at 140 ◦C. The crystallinity of the membranes 
was changed by the presence of both drugs. 
Mucoadhesion describes the bioadhesive bonding capacity that is 
established between a mucoadhesive polymer and the mucus layer onto 
the mucosal surface (Bassi da Silva et al., 2017). The mucoadhesion has 
been proposed as a way of prolonging the residence time of the product 
in a particular region, contributing to the increase of the therapeutic 
effect of the drugs. Thus, several materials with different bioadhesive 
characteristics aiming to increase adhesion to the mucous were pro-
posed, among them: CS, ALG, and HPMC (Caramella et al., 2015). 
Table 2 shows the adhesion results of the membrane. The presence of 
drugs did not significantly alter the adhesion properties of the mem-
branes. Moreover, CS and ALG have been previously described to 
possess mucoadhesive properties (Ahmad et al., 2018; Guadarrama- 
Acevedo et al., 2019), thus excellent adhesion properties of our mem-
branes were expected. 
The carboxyl and hydroxyl groups of the polymers are responsible 
for the formation of hydrogen bonds with the mucus layer, however, 
when introducing additional components, the strength and the 
mucoadhesive properties can be modified. Cationic polymers, such as 
CS, are excellent mucoadhesive materials, a property explained for the 
positive charge on their surface, being able to interact with the mucin 
negative molecules through electrostatic attraction (Frank et al., 2014). 
Anionic polymers, such as ALG, have carboxylic groups in their structure 
interacting through hydrogen bonding with oligosaccharides present in 
the mucin molecule, making up suitable adhesive materials (Khutor-
yanskiy, 2011). 
The mechanical properties are a parameter with significant impor-
tance since natural polymers have several limitations when compared to 
the synthetic ones, such as low tensile strength, elongation at break and 
higher flexibility (Ahmad et al., 2018; Guadarrama-Acevedo et al., 
2019). Table 3 shows the mechanical properties of F3 and F4 mem-
branes. The thickness, elongation, Young’s Modulus (MPa), and stress 
were evaluated. The F4 membrane exhibited higher stiffness and the 
greater force impressed at the moment of rupture (Tension) and better 
elongation compared to the F3 membrane. Statistically, the difference 
was significant when comparing them both. Instead, regarding to 
thickness, the difference was not statistically significant between F3 and 
F4 membranes. 
The loading of the drugs intimately influenced the mechanical 
properties in the F4 membrane, which indicates the potential increase in 
the intermolecular interactions (hydrogen bonds) that contributes to the 
rigidity of the structure. According to the literature, CS-ALG membranes 
exhibit a tensile strength at break of about 6 to 31 MPa (Bueno et al., 
2014); both F3 and F4 (before and after drug incorporation), showed a 
the membrane tension was higher than the reported values. The tensile 
stress of the epidermis without injury is between 5 and 30 MPa. Ac-
cording to Bueno et al. (Bueno et al., 2014), an increase in skin tension in 
moments of physiological stress, such as the appearance of a wound, is 
already promoted by the body itself and favours the cellular migration of 
fibroblasts, primary cells in tissue repair, therefore a biomaterial with 
good rupture stress assists in the cicatrizing process. 
Regarding the evaluation of the elastic properties of the membranes, 
there was a considerable increase in the values of the Young’s modulus, 
assuming that the less flexible the material, the higher this value, it can 
Fig. 4. DSC curves for membranes: ALG, CS, F3 (double layer without drug) 
and F4 (double-layer with the drug). 
Table 2 
Mean values of strength detachment and mucoadhesion.  
Sample Strength detachment (N) Mucoadhesion (N) 
F1 2.679 ± 0.282a,b 0.459 ± 0.190ª 
F2 2.795 ± 0.023a,b 1.001 ± 0.258ª 
F3 2.915 ± 0.242a,b 0.587 ± 0.379ª 
F4 2.785 ± 0.383a,b 0.842 ± 0.206ª 
Mean ± standard deviation of the replicates. Means with equal letters indicate 
that there is no significant difference (p < 0.05) in the property studied ac-
cording to the Tukey test. 
Table 3 
Mechanical properties of F3 and F4 membranes.  
Membranes Thickness 





(medium ± δ) 
Stress σ [MPa] 


















Different letters (a, b) in the same column indicate a significant difference 
(Tukey test at 95% confidence). Each value represents the mean ± S.D. (n = 3). 
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be expected that the loading of both drugs to the membranes will pro-
mote an increase of elasticity. The Young’s modulus indicates the 
hardness (rigidity) of the material when it is subjected to an external 
tension of tension, being the maximum tension those that the material 
supports without suffering any permanent deformation. Among the 
various characteristics of a dressing, maintaining its integrity during use 
is paramount. Therefore, the evaluation of this property is crucial to 
assist in the storage, handling, and application of the device. The 
modulation of the swelling forces promotes the improvement of poly-
meric biomaterials in several sectors, such as the food and pharmaceu-
tical industries (Fernandes et al., 2017). The membranes F1, F2, and F3 
did not remain intact when buried in phosphate buffer; the initial 
elevation can be explained considering that ALG and CS are poly-
saccharides with high hydrophilicity and, therefore, have a high 
absorbing capacity. This feature, at the primary stage of exposure to 
injured tissue, is essential for the application to exudative wounds. F4 
membrane showed a high absorption in the second hour of immersion, 
reaching 63.3% ± 0.00590 of degree of swelling, remaining constant 
and reaching the chemical balance in the process. The swelling is indeed 
considered the first stage of the mucoadhesion process and, in the 
presence of moisture, the polymers initiate contact with the mucosa, 
providing mechanical entanglement and formation of hydrogen bridges 
and/or electrostatic interactions between the polymer and the mucous 
network (Szekalska et al., 2017). 
Cell viability of the membranes was determined using an indirect 
method. Cell viability results (Fig. 5) show that membranes without the 
drug (F3) do not present a toxic effect, but not the membranes with the 
drug (F4). For the purpose of applying the membranes as controlled 
release systems, they must show no or very limited toxicity levels. Bueno 
et al. (Bueno et al., 2014) studied porous membranes of CS and ALG, 
showing that there were no adverse effects on cell growth. The observed 
cell viability reduction is related to PLX inherent toxicity, already re-
ported in several studies. The toxicological risk of using PLX is attributed 
to systemic distribution upon intravenous administration, being neph-
rotoxic in the long term. There is however a great difficulty in deter-
mining the real involvement of this drug in renal injury, because patients 
receiving PLX treatment do show several other factors that contribute to 
the nephrotic dysfunction (Brandenburg et al., 2012). 
The interaction between cells and artificial materials can occur 
directed through extracellular matrix ligand molecules or only through 
chemical bonds, such as hydrogen bonds between the cell membrane 
and polymer functional groups. However, this latter type of interaction 
does not favour the adhesion that cells require to survive. The attribute 
results from the ability in which the biomaterial adsorbs extracellular 
matrix molecules from the extracellular medium (either from in vitro 
culture medium or from body fluids in vivo). Efficient adsorption de-
pends on several factors associated with the material surface: hydro-
philicity/hydrophobicity, electric charge, topography, mechanical 
properties, crystallinity, porosity, solubility and the presence of specific 
functional groups (Othman et al., 2018). 
The membranes used for the adhesion test were fixed, as described in 
the methodology, and the surface was evaluated by SEM images (Fig. 6). 
Due to the double-layered nature of these membranes, the analysis was 
performed on both sides as follows: Side A and B belonging to F4 
membrane (Side A: ALG-PLX; Side B: CS-LC-PLX) and sides C and D (Side 
C: ALG and Side D: CS-HPMC-sorbitol) belonging to F3 membrane. 
The results show a significant difference between the adhesion of the 
membrane F4 and F3. On both sides of the drug membrane (F4), the 
most star-shaped cells proliferated and adhered around and between the 
pores of the membranes over the biomaterial. On the surface of F3, the 
observed differences that can be associated with polymers on both sides. 
On side C we have pure ALG, and almost no ordered cell activity or even 
distributed between the pores, in contrast to side D, where is CS alone 
and where cell adhesion is more significant with more clustered and 
shaped cells rounded. 
It is known that a cell with strong adhesion properties is in an 
extended form and spreads over a larger area. In contrast, when adhe-
sion is incipient, the cell adheres with a rounded shape, showing a 
minimal contact zone between the cell and the substrate; since most cells 
require adherence, they hardly survive under these conditions. When 
the adhesion force is higher, the contact area between the cell and the 
substrate is larger, forming multiple adhesion points, evolving to the 
proliferative phase and consequent differentiation. 
The antimicrobial activity of the samples is directly linked to their 
potency to inhibit the growth and multiplication of the microorganism 
in the presence of a presumed concentration of a tested antimicrobial 
agent. 
The obtained MIC values for Pseudomonas aeruginosa and Staphylo-
coccus aureus are promising results since they presented the same con-
centration values. The data for Staphylococcus aureus showed a MIC 
similar to that of Pseudomonas aeruginosa for CS of 7.8 μg⋅mL− 1, being 
the lowest concentration tested, thus confirming the antimicrobial ac-
tivity previously described in the literature (Insua et al., 2017). The MIC 
value recorded for PLX against both strains was 292.9 μg⋅mL− 1. ALG did 
not show any antimicrobial activity (0 μg⋅mL− 1) on both Staphylococcus 
aureus and Pseudomonas aeruginosa strains, thus suggesting no action in 
its pure form. However, when associated with PLX, it establishes a 
promising mechanism of inhibition, reaching a MIC value of 148.4 
μg⋅mL− 1. All constituents of the F4 double-layer membrane have their 
antimicrobial properties recognized in the literature (Severino et al., 
2015, 2017). For the double-layer membrane containing the drug PLX 
(F4), the MIC value was 144.5 μg⋅mL− 1 against both strains. The action 
of CS is established by the mechanism of interfering with bacterial 
metabolism by interacting the polymer molecules on the cell surface or 
acting by penetrating the membrane of the microorganism and then 
adsorbing into DNA molecules by blocking the transcription of RNA to 
DNA (Wang et al., 2017). 
Fig. 6 shows that the double-layer membrane containing the drug 
PLX (F4) presented an inhibition halo for the strains tested, demon-
strating that even the drug incorporated in the membrane had no loss of 
its antimicrobial activity. In contrast, this action was not observed in F3, 
which was not able to form a halo, corroborating the data recorded for 
the MIC testing. It should be noted that the absence of inhibition halo 
does not imply a complete antimicrobial inactivity, since the obtained 
membranes were able to prevent the growth of the tested 
Fig. 5. Effect of drug-free (F3) and drug (F4) double-layer polymer membranes 
on the viability assessment of human L929 fibroblasts determined by the MTT 
assay after 24 h of incubation. The negative control was treated with the vehicle 
used to dilute the drug (DMSO 5%) and as positive control: 0.02% phenol. The 
data correspond to the mean ± S.P.M. of four independent experiments. 
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microorganisms on their surfaces, which would make this biomaterial a 
candidate to act as a barrier against microorganisms (Fig. 7). 
In this study, animal healing experiments were performed using an in 
vivo biological model selected due to its easy acquisition, handling, ac-
commodation, resistance to surgical aggression and the low mortality 
presented in the infectious processes. Rat adults males were chosen in 
order to avoid hormonal variations of the female cycle that could 
interfere in the tissue repair mechanism (Mendes and de Jesus Souza, 
2017). Evaluation of the macroscopic aspect of wounds over time has 
been systematically performed in experimental studies to guide the most 
appropriate therapy (Zeugolis et al., 2018). Fig. 8 shows all group no 
signs of purulent exudation with no abscess formation in the inflam-
matory repair phases (03–07 days), and no deformed scars in the later 
stages (14–21 days). These data suggest that the healing process 
occurred uneventfully during the tests and that the developed bioma-
terial seems adequate to be used as a wound dressing (Song and Salcido, 
2011). No signs of self-aggression orbiting of other animals on the 
bloody area were observed, which also seems to suggest that the 
manipulation of the animals did not produce stress that interfered with 
their behaviour after performing the experimental procedures. 
The evaluation of the wound retraction index (WRI) over the 21 days 
of study is shown in Fig. 9. At day 3, the WRI of the control group (22.0 
± 1.79) was statistically similar to F3 (22, 34 ± 0.24) (p > 0.05). 
However, F4 had a significantly higher index in both groups (14.85 ±
1.16) (p < 0.001). At day 7, the FRI presented by the F3 group (85.98 ±
0.04) was significantly higher than control (37.75 ± 3.26) and F4 
(35.14 ± 0.63) (p < 0.001), but there was no significant difference be-
tween the last two (p > 0.05). After 14 days, the WRI obtained in groups 
F3 (92.10 ± 061) and F4 (90.55 ± 0.09) was significantly higher than in 
control (80.56 ± 3.98) (p < 0.001), but there was no difference between 
the two membranes tested (p > 0.05). 
Physiologically and in an orderly and efficient manner, wound heal is 
characterized by four distinct but overlapping phases, namely: hemo-
stasis, inflammation, proliferation, and remodelling. This complex pro-
cess needs to be tightly regulated to create a balanced molecular 
environment that allows healing (Olczyk et al., 2014). Regulation is 
based on various growth factors and cytokines that make up a complex 
signalling network that alters target cell growth, differentiation, and 
metabolism (Garcia-Orue et al., 2017). 
The F3 membrane (without drugs) presented better WRI during the 
Fig. 6. SEM after adhesion of L-929 cells for 48 h. Sides A and B belonging to membrane F4 (Side A: Sodium Alginate with Polymyxin B Sulphate; Side B: Chitosan 
with Lidocaine Chloride and Polymyxin B Sulphate) and Sides C and D for F3 Membrane (Side C: sodium and Side D: Chitosan, HPMC and sorbitol). 
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initial repair phase (on days 3 and 7), which was positive, considering 
that the development of this product modality is intended to be used for 
wound healing over all the distinct phases (Fig. 9a). Primary area where 
there is a high level of exudate and consequent formation of interstitial 
oedema, suggesting that among the polymeric components composing 
the membrane, there are anti-inflammatory properties that should be 
considered. 
CS dressings can accelerate the wound healing process through 
macrophage activation, increased number of fibroblasts, action on cell 
differentiation, and skin reepithelialisation (Debone et al., 2019). Upon 
hydrolysis, this biopolymer releases N-acetyl-β-D-glycosamine oligo-
mers which, when incorporated into extracellular matrix glycoproteins, 
activates these properties, stimulating and modulating the synthesis of 
natural hyaluronic acid which plays an essential role in the morpho-
genesis and inflammation process, promoting higher cell motility, 
adhesion, and proliferation. ALG is widely used in the production of 
dressings intended primarily for the management of exudative wounds, 
promoting absorption by ion exchange between the product and the 
exudate, resulting in the formation of a gel capable of maintaining a 
moist environment suitable for tissue granulation (Muzzarelli, 2009). 
Several studies have worked with associated CS and ALG dressings as 
blends, alone, or even as drug delivery systems and growth factors, 
helping in the positive evolution of tissue repair of several types of le-
sions (Bui et al., 2017; Gallardo-Rivera et al., 2018; Liu et al., 2018). 
On the other hand, the fact that the results observed in group F3 were 
more expressive than in F4 in the initial healing phases suggest the 
chemical modification of the membrane with their addition (Fig. 9b), as 
already seen in the previous characterizations. The use of topical anti-
microbials in uninfected wounds is still matter of intensive study; ac-
cording to Han and Ceilley (2017), they may delay the inflammatory 
phase. The indication for topical antibiotics is a clinically infected 
wound with purulent drainage, erythema, heat, pain, tenderness and/or 
hardening. Recent studies with the routine administration of antibiotics 
have led to better results, but often resulting in patient discomfort, along 
with the possibility of antibiotic resistance and contact dermatitis. 
The F4 membrane is designed for wound with a more difficult heal 
Bacteria Non-drug double layer 
membrane (F3) 
Double layer membrane with 





Fig. 7. The behavior of strains of Staphylococcus aureus and Pseudomonas aeruginosa tested against disc-shaped membranes, as a function of halo size of 
growth inhibition. 




Fig. 8. Macroscopic evaluation of the healing activity of F3 and F4 membranes in models of rat skin wounds over 21 days of the experiment.  
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process, e.g. those that are already infected or potentially contaminated 
due to manipulation or even biomechanics of the lesion, such as burns, 
skin trauma in environments or caused by contaminated objects, animal 
bites and scratches, vasculogenic ulcers, among others. This aim is 
reinforced by the evidence shown in Fig. 9(C and D) which corresponds 
to the final healing stages at days 14 and 21, when this bioproduct has 
achieved satisfactory WRI for such application. 
Han and Ceilley (2017) reinforce that under many conditions, the 
use of prophylactic antimicrobials in wounds is sometimes necessary, as 
the terms mentioned in the previous paragraph. A new study demon-
strates that microbiota, involving one or multiple species of the micro-
organisms present and propagating within the wound, is the leading 
underlying cause of chronic wound pathogenesis. Also, drug release 
dressings are favoured over traditional dressings because of their direct 
or indirect effects. Wound site antibiotic administration options are 
more effective, overcoming some of the disadvantages associated with 
systemic antibiotic administration (Naseri-Nosar and Ziora, 2018). 
From day 7 to day 14, the formation of granulation tissue was 
observed, with the high levels of TGF-β (Growth Transformation Factor) 
determine the beginning of active myofibroblastic differentiation in the 
scar area (Song and Salcido, 2011), to promote future contraction of the 
wound. After about 2–3 weeks, there was a remodelling where the 
collagen type is restored to usual (type I rather than type III) and the 
tissue matures. In our study, from day 14 onwards, the evolution of WRI 
in the F4 group was significantly higher than in the inflammatory phase, 
and both membranes (with and without drug) obtained an WRI statis-
tically higher than the control group, suggesting that their use consti-
tutes an advantage to the progress of healing. 
The histomorphological characteristics associated with the inflam-
matory/reparative process and collagen deposition, were analysed by 
haematoxylin/eosin (HE) and Picrosirius staining, and observing 
criteria established after a survey of the specialized literature by the 
Sultana et al. (2009) were adapted for this study and presented in 
Table 4. 
Scores 1 and 2 were discussed together and are shown in Fig. 10 
below. In both, the maximum score reflects the absence of the measured 
data, that is, when scored with 4, for example, that area was observed 
without granulation tissue (score 1) and without inflammatory infiltrate 
(score 2). Fig. 10A shows the presence and amount of granulation tissue 
evaluation. Over the three days of repair, statistical difference were 
observed between the group F3 and the control group (p = 0.0102) and 
also F3 in relation to F4 (p = 0.0062), which statistically resembles CTR 
(p = 0.9829), a fact that is repeated when we observed the evolution 
over seven days of experiment, but with a greater presence of granula-
tion in F3 compared to the three days. At day 14, no significant differ-
ence was observed between all groups (CTR vs F3: p = 0.8564; CTR vs 
F4: p = 0.8564; F3 vs F4: p > 0.9999), which is repeated at day 21 (CTR 
vs F3: p = 0.6515; CTR vs F4: p = 0.9829; F3 vs F4: p = 0.7596). 
Fig. 10B shows the intensity of inflammatory infiltrates over the days 
of the experiment. On day 3, no statistical difference was seen between 
all groups, showing an intense inflammatory activity, characteristic of 
this initial phase (CTR vs F3: p = 0.5200; CTR vs F4: p = 0.7464; F3 vs 
Fig. 9. Evaluation of wound retraction indexes (IRF) in the experimental groups over the time of the trial to evaluate the wound healing process. CTR (control group - 
uncoated wound), F3 (drug-free membrane-covered wound), F4 (drug-layered double-membrane wound). 
Table 4 
Evaluated parameters for healing score calculation.  
1 Amount of granulation tissue (intense-1, moderate-2, sparse-3, absent-4) 
2 Inflammatory infiltrate (intense-1, moderate-2, sparse-3, absent-4) 
3 Orientation of collagen fibers (irregularly arranged-1, mixed-2, parallel-3) 
4 Collagen pattern (reticular-1, mixed-2, fascicle-3) 
5 Amount of early collagen (intense-1, moderate-2, minimum-3, absent-4) 
6 Amount of mature collagen (intense-1, moderate-2, minimum-3) 
Scores 1 and 2: HE; scores 3–6: Picrosirius. 
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F4: p = 0.1685). At day 7, F3 stands out with a marked reduction in 
inflammation about the CTR group and F4 (p < 0.0001). At day 14, F4 
also presented a reduction in infiltrate, being similar to F3 (p = 0.7464) 
and both different from the CTR group, which remains with a moderate 
inflammation process (p < 0.0001). At day 21, all groups showed an 
absent and/or minimal inflammatory pattern, with no statistical dif-
ference between them. 
The histological analysis showed the expected physiological events 
Fig. 10. Distribution of values for Histological Analysis Scores 1 and 2 by the group surveyed during the 21 days of the experiment. A) Quantification of granulation 
tissue (intense-1, moderate-2, sparse-3, absent-4) with early evolution to F3 and later F4 equalization compared to F3. B) Inflammatory infiltrate (intense-1, 
moderate-2, sparse-3, absent-4) demonstrating a slower F4 exit from the early (acute inflammatory) stages of healing and later equalization with F3 within 14 days. 






Fig. 11. The histological sections (HE) of the groups 
(wounded areas) over time of the biological wound 
healing trial, where CTR (control group), without 
coverage; F3 – membrane without drug; F4 – mem-
brane with the drug; Intense neutrophilic infiltrate is 
visualized at three days, and granulation tissue at 
seven days. At 14 days, replacement of granulation 
tissue with a primary fibrous scar is seen in all groups. 
At 21 days the fibrous scar tissue is denser at F3 and 
F4. Characteristics of the dermal epithelium with 
formation of dermal appendages only observed in 
membrane-treated wounds.   
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of the healing process in each period (Fig. 11). The statistical differences 
observed in HE histology reflect the physiological evolution observed in 
scar retraction, where the drug membrane (F4) shows a different 
development compared to F3. The wounds treated with F4 showed 
higher inflammatory density than the others, including the presence of 
intense infiltration at seven days of the experiment. 
As the structural difference between the membranes in the presence 
of drugs, PLX, and LC, the justifications for such prolongation of acute 
inflammation may lie in these. The effect of LC has been studied together 
with other local anesthetics under wound healing. Kesici et al. (2018) 
and Waite et al. (2010) reported that the drug in question did not cause 
favourable and/or unfavourable changes in the healing of lesions in its 
inflammatory phase. With PLX, the literature states that, like most 
topical antibiotics, it promotes slight toxicity on cell migration during 
healing, especially on the polarization of keratinocytes that will restore 
the epithelial barrier (Brothers et al., 2015). 
PLX also shows chemical structure with a fatty acid at its end which 
may suggest some interference with the healing process, given that the 
modulation of the inflammatory response by fatty acids in healing is not 
yet well established. Studies address the benefits of these substances, 
such as accelerating the inflammatory phase and stimulating new vessel 
formation (Rodrigues et al., 2016) while others point out negative as-
pects such as delayed healing due to prolonged maintenance of the in-
flammatory phase (Turk et al., 2013). 
At day 14, F4 evolves reaching F3 in the proliferative or maturation 
phases, not differing significantly from each other. The same result is 
observed at day 21 when the maturation phase predominated in both 
groups. The recommendation for the use of F4, already made in this 
study, for colonized lesions or with high potential for infection (asso-
ciated with the cause or another factor, such as patient immunosup-
pression), corroborates the literature stating that the use of topical 
antibiotic therapy should be restricted to the cases mentioned. 
Scores 3 and 4 begin the assessment with picrosirius staining and are 
shown in Fig. 12. Both refer to the structure of presentation of collagen 
fibers in orientation (irregularly arranged-1, mixed-2, parallel-3) and 
standard, respectively (reticular-1, mixed-2, fascicle-3). Regarding the 
orientation of the fibers (Fig. 12A), the groups F3 and F4 (p = 0.0311) 
with F3 are already statistically different at the three days of repair, 
alternating with the organization of the collagen fibers and F4 still 
irregularly arranged. At seven days, F3 is already mixed and CTR and F4 
continue with an irregular pattern regarding the measured score, with 
no statistical difference between the last two (CTR vs F3: p = 0.0012; 
CTR vs F4: p = 0, 7776; F3 vs F4: p = 0.0065). At 14 and 21 days, the 
groups had no significant difference, migrating orientation at the end of 
the analyzed repair period to the parallel organization of their fibers. 
Score 4 (Fig. 12B) showed that F3 was statistically significantly 
different from both the control (p = 0.0006) and F4 (p = 0.0006) groups 
in the initial three days. F4 statistically resembles the CTR group (p =
>0.9999). In seven days, F3 and F4 have already matched (p = 0.0932). 
At day 14 and day 21, F3 and F4 remain statistically similar, reaching 
the fascicular pattern at the end of the analyzed period, differing from 
the CTR group that remained with a mixed collagen pattern. 
Scores 5 and 6, also analyzed with picrosirius, reflect the indirect 
quantification of early (type III collagen) and mature (type I collagen) 
collagen of the analyzed slides within 21 days (Fig. 13). The scoring 
pattern follows as intense-1, moderate-2, minimum-3, absent-4, the 
latter not being considered for score 6. Under statistical analysis, the 
groups differed in the initial repair phases, 3 days, where we can observe 
the presence of early collagen (score 5 – Fig. 13A) at the beginning of F3 
healing, in contrast to the other groups, between F4 and control group 
there was no significance (CTR vs F3: p < 0.0001; CTR vs F4: p =
>0.9999; F3 vs F4: p = <0.0001). At 7, 14 and 21 days there was no 
difference between the groups, physiologically evolving the healing 
process regarding the quantitative measurement of early collagen. 
Type I collagen deposition was assessed using score 6 (Fig. 13B). The 
drug-free membrane, F3, showed the early presence of mature collagen 
with difference for F4 and CTR (p < 0.0001) at three and seven days. At 
day 14, both membranes were moderately mature and statistically 
similar (p = 0.3497) with a difference for the control group (p =
0.0008). At day 21, the presence of type I collagen in F3 and F4 was 
already assessed as intense (p > 0.9999), unlike CTR (p = 0.0008). 
The collagen deposition, were observed, which indicated that the 
physiological events expected at each healing phase were adequate 
(Fig. 14). At three days, there were greenish/yellowish-green collagen 
type III fibrils, of varying sizes present in all groups, but in F3 there was a 
visually better evolution of fiber organization, from the reticular to the 
mixed pattern. Groups F4 and CTR showed reticular and small amounts 
of arrangement (Fig. 14). 
At seven days, the statistical difference between F3 and F4 still 
prevails, with the advance in the healing stage of the group treated with 
the drug-free membrane (F3). In general, considering the amount of 
collagen and its fiber disposition, there is a better healing evolution of 
the treated groups to the control group. 
Alsarra et al. (2002) reported that CS stimulates, in the early stages of 
healing, the migration of inflammatory cells, growth factors resulting in 
angiogenesis and formation of earlier granulation tissue. However, the 
delay in the resolution of the inflammatory process of F4, already 
justified by the presence of PLX, results in decreased migration and 
Fig. 12. Distribution of values for Histological Analysis Scores 3 and 4 by group surveyed during the 21 days of the experiment. (A) The orientation of collagen fibers 
(irregularly arranged-1, mixed-2, parallel-3). (B) Collagen pattern (reticular-1, mixed-2, fascicle-3). 
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Fig. 13. Distribution of values for Histological Analysis Scores 5 and 6 by the group surveyed during the 21 days of the experiment. (A) Amount of early collagen 







Fig. 14. Collagen deposition in experimental groups during 21 days of study. Days three and seven with predominance of thin type III (greenish/yellowish) collagen 
fibers in F4 and CTR, while in F3 there is already a replacement for denser fibers with a reddish birefringence. Day 14 fibers replaced in F3 and F4 for more mature 
collagen. At 21 days, all groups had intertwined type I collagen fibers. 
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cellular activity of this group. 
At day 21, all groups that used the F3 and F4 membranes as wound 
cover showed better retraction rates and histological aspects than the 
control group. These findings, therefore, suggest that the use of dressings 
for these wounds may be advantageous to the healing process. 
4. Conclusions 
This study described the development of a biocompatible double 
layer membrane based on biopolymers (chitosan and sodium alginate) 
for the delivery of polymyxin sulphate and lidocaine chloride, for wound 
healing. A scalable and organic solvent-free production procedure has 
been adopted to develop a non-toxic, of low-cost biomaterial. The ob-
tained product was shown to be non-cytotoxic against fibroblasts. Its 
antimicrobial activity was confirmed in vitro using Gram-positive 
(Staphylococcus aureus) and Gram-negative (Pseudomonas aeruginosa) 
bacteria. The wound healing capacity of double layer membrane was 
confirmed in vivo, showing promising outcomes to be applied in human 
studies. 
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